ClinicalTrials.gg
Not yet recruitingNCT07535970Updated Apr 17, 2026

A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Participants

A Phase 1 interventional study of HS-10506, Itraconazole in Healthy Participants, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A single-center, open-label, fixed-sequence, self-controlled phase I clinical trial aimed at evaluating the effect of itraconazole capsules(CYP3A inhibitor) on the pharmacokinetics of HS-10506 tablets in healthy participants.

Read the detailed description

On Day 1 and Day 11 of the trial, HS-10506 tablets will be orally administered under fasting conditions in the morning. From Day 7 to Day 15, itraconazole capsules (0.2 g, administered as two 0.1 g capsules) will be taken orally once daily for nine consecutive days. On the morning of Day 11, itraconazole capsules and HS-10506 tablets will be taken concurrently. When administered alone or in combination with itraconazole capsules, HS-10506 tablets will be given under fasting conditions. When administered alone, itraconazole capsules will be taken within 15 minutes after a meal, with approximately 240 mL of water.

02

Conditions studied

  • Healthy Participants

Keywords

  • Phase 1
  • Drug interaction
  • Itraconazole
  • HS-10506
  • Healthy Participants
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form before the trial, fully understand the trial content, procedures, and possible adverse events, and self-report the ability to complete the study in accordance with the trial regulations;
  2. Adult males and females (aged between 18 and 45 years, inclusive of boundary values, calculated on the date of signing the informed consent form);
  3. Participant's (BMI) = weight (kg) / height² (m²) within the range of 19.0-26.0 kg/m² (inclusive of boundary values); male participants weigh ≥ 50 kg, female participants weigh ≥ 45 kg;
  4. Agree to practice highly effective from the signing of the informed consent form until 3 months after the last dose, and have no plans for pregnancy or sperm/egg donation during this period (only non-drug contraceptive measures are permitted during the trial).

Exclusion criteria

Exclusion Criteria:

  1. Those with abnormalities in physical examination, vital signs, oxygen saturation, 12-lead , clinical laboratory tests, etc., deemed by the investigator as unsuitable for enrollment;
  2. Positive results for any one or more of surface antigen, antibody, antibody, or Treponema pallidum(TP)specific antibody during the screening period;
  3. 12-lead electrocardiogram results during the screening period showing >450.00 ms for males or QTcF>470.00 ms for females;
  4. Previous or current presence of severe diseases of the nervous system, psychiatric system, digestive system, circulatory system, respiratory system (e.g., anatomical abnormalities of the airway, congenital microstomia with macroglossia, mandibular hypoplasia; or sleep apnea syndrome), urinary system, endocrine and metabolic system, immune system, hematological system, etc., assessed by the investigator as unsuitable for participation in this study;
  5. Current or past history of psychiatric disorders or brain dysfunction, or assessment of suicide risk using the Columbia-Suicide Severity Rating Scale (C-SSRS), or self-injurious behavior or suicide attempt within one year before screening, or current suicide risk based on the investigator's clinical judgment;
  6. Current or past history of severe gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis, reflux esophagitis, etc.);
  7. Evidence of previous ventricular dysfunction, such as congestive heart failure (CHF)or a history of CHF;
  8. History of surgery within 3 months before screening, or planned surgery during the trial period, or surgery that may affect drug absorption, distribution, metabolism, or excretion, deemed by the investigator as unsuitable for enrollment;
  9. Participation in any other clinical trial involving any drug or device within 3 months before screening, or within 7 half-lives of another investigational drug before screening, whichever is longer;
  10. Prone to allergic reactions, or allergic constitution(e.g., allergies to pollen, two or more drugs/foods), or known allergy to components of HS-10506 tablets or itraconazole capsules;
  11. History of drug abuse, drug dependence, or use of illicit drugs within 5 years before screening, or positive drug abuse screening results;
  12. Frequent alcohol consumption within 3 months before screening (i.e., consuming more than 14 units of alcohol per week; 1 unit = 14 g alcohol, equivalent to 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine, equivalent to 10 bottles of beer, 500 mL spirits, or 3 bottles of wine per week), or inability to stop consuming alcoholic products during the trial, or positive alcohol breath test;
  13. Average daily smoking of more than 5 cigarettes within 3 months before screening, or inability to stop using any tobacco products during the trial;
  14. Excessive consumption of tea, coffee, and/or caffeinated beverages within 3 months before screening (average of more than 8 cups per day; 1 cup = 200 mL);
  15. Significant blood loss(≥200 mL)or blood donation within 3 months before screening, or plans for blood donation during the study or within 3 months after the study;
  16. Use of any drugs affecting , CYP2C19 enzymes, or drugs altering gastric acid [proton pump inhibitors (PPIs), H2 receptor antagonists, topical antacids, oral alkaline drugs, etc.] within 30 days before the first dose of investigational product(or within 7 times the corresponding elimination half-life, whichever is longer);
  17. Use of any prescription drugs, over-the-counter drugs, herbal medicines, or health supplements(excluding topical preparations with local effects) within 14 days before the first dose of investigational product, or use of any drug within 7 half-lives (whichever is longer);
  18. Consumption of grapefruit or grapefruit products within 48 hours before the first dose of investigational product;
  19. Vaccination within 30 days before the first dose of investigational product, or planned use of vaccines during the study or within two weeks after the study;
  20. Significant changes in diet or sleep habits within 4 weeks before screening, assessed by the investigator as unsuitable for participation in this study;
  21. Female participants who are pregnant, breastfeeding, or have a positive pregnancy test result within 1 month before screening or during the trial period;
  22. Unprotected sexual intercourse within 14 days before screening;
  23. Special dietary requirements, inability to comply with a unified diet, or difficulty swallowing;
  24. Intolerance to venipuncture/indwelling needle blood collection or fear of needles/blood;
  25. Inability to complete the study for other reasons or deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Drug-drug interaction Arm

    Drug: HS-10506, Itraconazole

Interventions

  • DrugHS-10506, Itraconazole

    Drug pages: HS-10506 · Itraconazole

    HS-10506: Administered under fasting conditions in the morning. Itraconazole: Itraconazole capsules (0.2 g) are taken orally once daily for nine consecutive days.

06

What researchers measure

Primary outcomes

  1. Evaluation of PK parameters of HS-10506: Cmax

    To evaluate the Cmax of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: 120 hours after administration of HS-10506

  2. Evaluation of PK parameters of HS-10506: AUC0-t

    To evaluate the AUC0-t of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: 120 hours after administration of HS-10506

  3. Evaluation of PK parameters of HS-10506: AUC0-∞

    To evaluate the AUC0-∞ of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: 120 hours after administration of HS-10506

Secondary outcomes

  1. Evaluation of PK parameters of HS-10506:Tmax

    To evaluate the Tmax of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: 120 hours after administration of HS-10506

  2. Evaluation of PK parameters of HS-10506: t1/2z

    To evaluate the t1/2z of HS-10506 administered alone and in combination with Itraconazole in healthy participants

    Time frame: 120 hours after administration of HS-10506

  3. Evaluation of PK parameters of HS-10506: λz

    To evaluate the λz of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: 120 hours after administration of HS-10506

  4. Evaluation of PK parameters of HS-10506: CL/F

    To evaluate the CL/F of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: 120 hours after administration of HS-10506

  5. Evaluation of PK parameters of HS-10506: Vz/F

    To evaluate the Vz/F of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: 120 hours after administration of HS-10506

  6. Evaluation of PK parameters of HS-10506: MRT0-t

    To evaluate the MRT0-t of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: 120 hours after administration of HS-10506

  7. Evaluation of PK parameters of HS-10506: MRT0-∞

    To evaluate the MRT0-∞ of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: 120 hours after administration of HS-10506

  8. Adverse events

    To evaluate the adverse events (AEs) of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

  9. blood pressure

    To evaluate the blood pressure of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

  10. Pulse

    To evaluate the Pulse of HS-10506 administered alone and in combination with Itraconazole in healthy participants

    Time frame: through study completion, an average of 36 days

  11. body temperature

    To evaluate the body temperature of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

  12. oxygen saturation

    To evaluate the oxygen saturation of HS-10506 administered alone and in combination with Itraconazole in healthy participants

    Time frame: through study completion, an average of 36 days

  13. complete blood count (CBC)

    To evaluate the abnormal of complete blood count (CBC)of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

  14. urinalysis

    To evaluate the abnormal of urinalysis of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

  15. blood chemistry

    To evaluate the abnormal of blood chemistry of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

  16. coagulation tests

    To evaluate the abnormal of coagulation tests of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

  17. thyroid function test (TFT)

    To evaluate the abnormal of thyroid function test (TFT) of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

  18. Physical examination (include skin, mucous membranes and lymph nodes; head and neck; chest; abdomen; spine and extremities; nervous system, etc)

    To evaluate the abnormal of physical examination of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

  19. 12-lead electrocardiogram (include heart rate, PR, RR, QRS duration, QT interval and QTcF)

    To evaluate the abnormal of 12-lead electrocardiogram of HS-10506 administered alone and in combination with Itraconazole in healthy participants.

    Time frame: through study completion, an average of 36 days

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Jul 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Apr 17, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Jul 30, 2026
CompletionEst.
Jul 30, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07535970
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Jul 30, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
Apr 17, 2026

Study contacts

Wei Zhao, Doctor
Contact
zhao4wei2@hotmail.com
0531-82169023
Wen Shu Yu, Doctor
Contact
yaoxuebu2012@163.com
0531-82169023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HS-10506 · Itraconazole

Start the discussion